Poster Presentation Advances in Neuroblastoma Research Congress 2016

Reduced endoplasmic reticulum (ER)-mitochondria tethering as a cause of multidrug resistance in neuroblastoma (#246)

Jorida Coku 1 , Elizabeth O Scadden 1 , Kangning Liu 1 , Annette Vu 1 , David M Booth 2 , Michelle Chen 1 , Sharon Kim 1 , Renata Sano 1 , Yael Mosse 1 , Patrick Reynolds 3 , Hajnóczky Hajnóczky 2 , Michael D Hogarty 1
  1. University of Pennsylvania, Philadelphia, PA, United States
  2. Thomas Jefferson University, Philadelphia, PA, USA
  3. Texas Tech University Health Sciences Center, Lubbock, TX, USA

Background: High-risk neuroblastoma patients often respond to therapy before relapsing with lethal multidrug-resistant disease. We propose loss of ER-mitochondria physical tethering, selected for during therapy, contributes to drug resistance.

Methods: We studied isogenic neuroblastoma cell line pairs derived from the same patients both at diagnosis (DX) and progressive disease on/after chemotherapy (PD). Tumor-isolated mitochondria were studied for functional responses to death stimuli (BH3 profiling), biomass (citrate synthase activity), and mtDNA (content by qPCR; sequence by MitoChip v2.0). Electron microscopy (EM) was used to quantify ER-mitochondria morphology and tethering. The impact of chemical and genetic manipulation of tethering on mitochondrial response and chemosensitivity was assessed.

Results: DX/PD pairs showed no changes in mitochondrial biomass or mtDNA. However, 7/7 pairs showed markedly attenuated cytochrome c release at relapse in response to tBid and BimBH3 peptides (terminal death effectors downstream of therapeutic stress), corresponding to relative chemotherapy resistance (up to 800-fold across diverse agent classes). Marked reductions in ER-mitochondria tethering (up to 70%) were seen by EM in post-relapse tumors. Attenuated mitochondrial responses were phenocopied by limited protelolysis of ER from mitochondria in DX (sensitive) lines, as well as by enforced de-tethering using a cyclophilin-D inhibitor; extent of mitochondrial attenuation was proportional to chemoresistance. A similar phenotype was observed in ALK-mutant cells selected for ALK-inhibitor resistance, leading to mitochondrial attenuation and broad therapy resistance.

Conclusions: We identify a novel contributor to multidrug resistance attributable to attenuated mitochondrial stress-responses. Our data support this attenuation derives from reduced ER-mitochondrial tethering with consequent loss of ER-derived signals required for mitochondrial competency. This mechanism is not exclusive to any other contributor to therapeutic resistance and may also contribute to resistance to targeted agents. Altered ER-mitochondria tethering has been linked to neurodegeneration and diabetes suggesting regulation of this inter-organelle contact may have broad relevance to human disease.